Role of tissue plasminogen activator and plasminogen activator inhibitor polymorphism in myocardial infarction
- 183 Downloads
A case–control association study on 229 Myocardial Infarction (MI) patients and 217 healthy controls was carried out to determine the role of tissue-plasminogen activator (t-PA) (Alu-repeat insertion (I)/deletion (D)) and plasminogen activator inhibitor (PAI-1) (4G/5G insertion/deletion) polymorphisms with MI in the Pakistani population. In MI patients the genotype distribution of the PAI-1 gene was not found to be different when compared with the unaffected controls (P > 0.05, χ2 = 1.03). The risk allele 4G was also not associated with MI (P > 0.05, χ2 = 0.46, odds ratio (OR) = 1.1 (95% confidence interval (CI) = 0.84–1.43), P > 0.05). Similarly, the genotype frequencies of t-PA I/I, I/D and D/D were not different from the unaffected controls (P > 0.05, χ2 = 1.60), and the risk allele “I” was not found to be associated with MI (P > 0.05, χ2 = 1.35, OR = 0.86 (95% CI = 0.66–1.11), P > 0.05). However, when the data were distributed along the lines of gender a significant association of the 4G/4G PAI-1 genotype was observed with only the female MI patients (P < 0.05, z-test = 2.21). When the combined genotypes of both the polymorphisms were analyzed, a significant association of MI was observed with the homozygous DD/4G4G genotype (P < 0.01, z-test = 2.61), which was specifically because of the female samples (P = 0.01, z-test = 2.53). In addition smoking (P < 0.001, χ2 = 13.52, OR = 3.45 (95% CI = 1.77–6.94)), diabetes (P < 0.001, χ2 = 22.45, OR = 8.89 (95% CI = 2.96–29.95)), hypertension (OR = 7.76 (95% CI = 2.88–22.68), P < 0.001) family history (P < 0.001, χ2 = 13.72, OR = 3.7 (95% CI = 1.71–8.18)) and lower HDL levels (P < 0.05) were found to be significantly associated with the disease. In conclusion the PAI-1 gene polymorphism was found to have a gender specific role in the female MI patients.
KeywordsMyocardial infarction Tissue-plasminogen activator Plasminogen activator inhibitor Coronary artery disease
We would like to thank all the subjects for donating their blood. This work was financially supported by Grant No. 934 from the Higher Education Commission of Pakistan, awarded to RQ. Part of this work was supported by Shifa College of Medicine through a core grant.
- 3.Pinchuk M (2007) World health statistics 2007. WHO Press, GenevaGoogle Scholar
- 4.Theakston F (2008) World health statistics 2008. WHO Press, GenevaGoogle Scholar
- 16.Soysal D, Emuroglu T, Biceroglu S, Cevik C, Ulusoy S, Cengiz NK, Cetinkaya GS (2006) The association of Plasma PAI-1 and t-PA antigen concentrations with related cardiac risk factors in their first-degree relatives. Turkiye Klinikleri J Cardiovasc Sci 18:4–12Google Scholar
- 18.Sambrook J, Russell DW (2001) Molecular cloning: a laboratory manual, vols I and II, 3rd edn. Cold Spring Harbor Laboratory Press, Cold Spring HarborGoogle Scholar
- 24.Hooper WC, Lally C, Austin H, Renshaw M, Dilley A, Wenger NK, Phillips DJ, Whitsett C, Rawlins P, Evatt BL (2000) The role of the t-PA I/D and PAI-1 4G/5G polymorphisms in African-American adults with a diagnosis of myocardial infarction or venous thromboembolism. Thromb Res 99:223–230PubMedCrossRefGoogle Scholar
- 28.Jafary MH, Samad A, Ishaq M, Jawaid SA, Ahmed M, Vohra EA (2007) Profile of acute myocardial infarction (AMI) in Pakistan. Pak J Med Sci 23:485–489Google Scholar
- 30.Juhan-Vague I, Morange PE, Frere C, Aillaud MF, Alessi MC, Hawe E, Boquist S, Tornvall P, Yudkin JS, Tremoli E, Margaglione M, Di Minno G, Hamsten A, Humphries SE, HIFMECH Study Group (2003) The plasminogen activator inhibitor-1 −675 4G/5G genotype influences the risk of myocardial infarction associated with elevated plasma proinsulin and insulin concentrations in men from Europe: the HIFMECH study. J Thromb Haemost 1:2322–2329PubMedCrossRefGoogle Scholar
- 33.Glueck CJ, Phillips H, Cameron D, Wang P, Fontaine RN, Moore SK, Sieve-Smith L, Tracy T (2000) The 4G/4G polymorphism of the hypofibrinolytic plasminogen activator inhibitor type 1 gene: an independent risk factor for serious pregnancy complications. Metabolism 49:845–852PubMedCrossRefGoogle Scholar